Passa al contenuto
Merck

Epidemiology of candidemia in Latin America: a laboratory-based survey.

PloS one (2013-03-26)
Marcio Nucci, Flavio Queiroz-Telles, Tito Alvarado-Matute, Iris Nora Tiraboschi, Jorge Cortes, Jeannete Zurita, Manuel Guzman-Blanco, Maria Elena Santolaya, Luis Thompson, Jose Sifuentes-Osornio, Juan I Echevarria, Arnaldo L Colombo
ABSTRACT

The epidemiology of candidemia varies depending on the geographic region. Little is known about the epidemiology of candidemia in Latin America. We conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American countries. Incidence rates were calculated and the epidemiology of candidemia was characterized. Among 672 episodes of candidemia, 297 (44.2%) occurred in children (23.7% younger than 1 year), 36.2% in adults between 19 and 60 years old and 19.6% in elderly patients. The overall incidence was 1.18 cases per 1,000 admissions, and varied across countries, with the highest incidence in Colombia and the lowest in Chile. Candida albicans (37.6%), C. parapsilosis (26.5%) and C. tropicalis (17.6%) were the leading agents, with great variability in species distribution in the different countries. Most isolates were highly susceptible to fluconazole, voriconazole, amphotericin B and anidulafungin. Fluconazole was the most frequent agent used as primary treatment (65.8%), and the overall 30-day survival was 59.3%. This first large epidemiologic study of candidemia in Latin America showed a high incidence of candidemia, high percentage of children, typical species distribution, with C. albicans, C. parapsilosis and C. tropicalis accounting for the majority of episodes, and low resistance rates.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Fluconazole, ≥98% (HPLC), powder
Supelco
Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material
Fluconazole, European Pharmacopoeia (EP) Reference Standard
Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard